This was back from 2015 when these "new" antibodies had remained sealed from the public as most things seem to be for now and these results were likey what Dr Jedd Wolchok was supposed to talk about at Keystone Jan 16-20 before "an emergency" came up
Dr Jedd Wolchok : Keystone Symposia round 2 and didn't Bank of Montreal buy PPHM/CDMO ..
Cancer Immunotherapy: Combinations (C5) Scientific Organizers: Chris Boshoff, Lieping Chen and Lisa Coussens
March 23—27, 2018 Fairmont The Queen Elizabeth, Montreal, Québec, Canada
Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to the generous support from an anonymous donor.
Sponsored by AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cancer Research UK, Cell Research, Incyte Corporation, MedImmune, Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology,Takeda Pharmaceutical Company Limited, TESARO, Inc. and Thermo Fisher Scientific Inc.
IT’S NOT TOO LATE TO SUBMIT YOUR ABSTRACT. Abstracts received can no longer be considered for oral short talks. Abstracts for poster display opportunities will be accepted until 6 weeks before meeting start date midnight MST. BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
DEADLINES: *All deadlines end at 11:59 PM US Mountain Standard Time Scholarship Deadline: Nov 21, 2017 [details] Discounted Abstract Deadline: Nov 21, 2017 [details] Abstract Deadline: Dec 19, 2017 [details] Discounted Registration Deadline: Jan 16, 2018 [details]
Click here to view Cancellation Policy
Submit an Abstract Register Yourself Deadlines and Fees
No registration fees are used to fund entertainment or alcohol at this conference
Conference Program Print | View meeting in 24 hr (international) time
The meeting will begin on Friday, March 23 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Tuesday, March 27 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Wednesday, March 28 in order to fully experience the meeting.
FRIDAY, MARCH 23
4:00—8:00 PM Arrival and Registration
Foyer C 6:00—8:00 PM Welcome Mixer No registration fees are used to fund alcohol served at this function.
Av. Laurier
SATURDAY, MARCH 24
7:30—8:30 AM Breakfast
Square Dorchester/Parc Mont Royal 8:30—10:00 AM Welcome and Keynote Session Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, USA Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms
Elizabeth M. Jaffee, Johns Hopkins University, USA Combinatorial Immunotherapy Converts Pancreatic Cancers Into An Immunologic Disease
Coffee Break
10:20 AM—12:00 PM Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Lieping Chen, Yale University, USA Design of Combination Therapy Based Adaptive Resistance Mechanisms in Tumor Microenvironment
Michele W. Teng, QIMR Berghofer Medical Research Institute, Australia Dissecting the Immunological Mechanisms underlying the Efficacy of Neoadjuvant Immunotherapy
Short Talk(s) Chosen from Abstracts
12:00—5:00 PM On Own for Lunch
12:00—1:00 PM Poster Setup
Square Dorchester/Parc Mont Royal 1:00—10:00 PM Poster Viewing
Square Dorchester/Parc Mont Royal 2:30—4:30 PM Workshop: Biomakers and Patient Selection Strategies for Immunotherapy Combinations
Place du Canada Short Talks Chosen from Abstracts
4:30—5:00 PM Coffee Available
Square Dorchester/Parc Mont Royal 5:00—7:00 PM Incorporating Checkpoint Inhibitors into SOC Chemo- and Radiotherapy Regimens Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Speaker to be Announced
Andy Minn, University of Pennsylvania, USA Interferon Driven Resistance Mechanisms to Immune Checkpoint Blockade Combination Therapy
Bahija Jallal, MedImmune, Inc., USA Combination Therapy for Cancer: Beyond Checkpoint Inhibition
Short Talk Chosen from Abstracts
7:00—8:00 PM Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.
Square Dorchester/Parc Mont Royal 7:30—10:00 PM Poster Session 1
Square Dorchester/Parc Mont Royal
SUNDAY, MARCH 25
7:30—8:30 AM Breakfast
Square Dorchester/Parc Mont Royal 8:30—11:30 AM Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Lisa M. Coussens, Oregon Health & Science University, USA Dynamic Interactions Between Myeloid and Lymphoid cells Regulate Response to Therapy in Solid Tumors
Judith A. Varner, University of California, San Diego, USA Targeting Tissue Resident Macrophages and Their Progenitors To Suppress Cancer Progression
Coffee Break
Chris H. Boshoff, Pfizer Inc., USA Combining Checkpoint Inhibitors with Targeted Therapies
Jane L. Grogan, Genentech, Inc., USA Epigenetic Regulation of Tumor-associated Myeloid Cell Activity by CBP/EP300 Bromodomain
Short Talk(s) Chosen from Abstracts
11:30 AM—5:00 PM On Own for Lunch
11:30 AM—1:00 PM Poster Setup
Square Dorchester/Parc Mont Royal 1:00—10:00 PM Poster Viewing
Square Dorchester/Parc Mont Royal 4:30—5:00 PM Coffee Available
Square Dorchester/Parc Mont Royal 5:00—7:00 PM Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Sergio A. Quezada, University College London, UK Using Preclinical Models and Clinical Samples to Inform Rational Combinations
Jo A. Van Ginderachter, VIB-Vrije Universiteit Brussel, Belgium Tumor-Associated Dendritic Cell Sub-Populations in Cancer Immunity
Bernard A. Fox, Earle A Chiles Research Institute, USA Sequencing Checkpoint Therapies
Short Talk Chosen from Abstracts
7:00—8:00 PM Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.
Square Dorchester/Parc Mont Royal 7:30—10:00 PM Poster Session 2
Square Dorchester/Parc Mont Royal
MONDAY, MARCH 26
7:30—8:30 AM Breakfast
Square Dorchester/Parc Mont Royal 8:30—11:30 AM Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Peter S. Hammerman, Novartis Institutes for Biomedical Research, USA Adaptive Resistance to Immune Checkpoint Blockade
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA Molecular and epigenetic programs defining tumor-specific T cell dysfunction
Coffee Break
Gregory Lawrence Beatty, University of Pennsylvania, USA Strategies for Incorporating CD40 Agonists in Cancer Therapy
Yong-Jun Liu, Sanofi, USA Talk Title to be Announced
Short Talk(s) Chosen from Abstracts
11:30 AM—5:00 PM On Own for Lunch
11:30 AM—1:00 PM Poster Setup
Square Dorchester/Parc Mont Royal 1:00—10:00 PM Poster Viewing
Square Dorchester/Parc Mont Royal 4:30—5:00 PM Coffee Available
Square Dorchester/Parc Mont Royal 5:00—7:00 PM Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Douglas T. Fearon, Cold Spring Harbor Laboratory, USA CXCR4 Mediates Immune-Privilege in T Cell-Excluded Tumors
Daniela F. Quail, McGill University, Canada Macrophage and T Cell Interactions in the Brain Tumor Microenvironment
Hiroyoshi Nishikawa, National Cancer Center Japan, Japan Control of Tumor-Associated Regulatory T Cells for Effective Cancer Immunotherapy
Short Talk Chosen from Abstracts
7:00—8:00 PM Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.
Square Dorchester/Parc Mont Royal 7:30—10:00 PM Poster Session 3
Square Dorchester/Parc Mont Royal
TUESDAY, MARCH 27
7:30—8:30 AM Breakfast
Square Dorchester/Parc Mont Royal 8:30—11:30 AM Vaccines, Oncolytic Viruses and Cellular Therapies: Towards Combinations Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Stephen H. Thorne, University of Pittsburgh, USA Oncolytic Viruses to Sensitize Resistant Tumors to Immunotherapy
Jeffrey Weber, NYU Langone Medical Center, USA Clinical Efficacy and Biomarker Analyses in Patients Receiving Adjuvant Checkpoint Blockade for Resected High-Risk Stages III/IV Melanoma
Coffee Break
Olivera J. Finn, University of Pittsburgh School of Medicine, USA Vaccines for Prevention of Non-viral Cancers
Gerald P. Linette, University of Pennsylvania, USA Melanoma Neoantigen Discovery and Clinical Validation
Short Talk(s) Chosen from Abstracts
11:30 AM—5:00 PM On Own for Lunch
4:30—5:00 PM Coffee Available
Square Dorchester/Parc Mont Royal 5:00—6:45 PM CTLA-4: Novel Molecules and Approaches to Combinations Registered attendees can view abstracts starting on 02/23/2018
Place du Canada Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
Mario Sznol, Yale School of Medicine, USA Lessons Learned from Anti-PD-1 and Anti-CTLA-4 Combinations
Alan J. Korman, Bristol-Myers Squibb, USA Next Generation Anti-CTLA-4 Antibodies
6:45—7:00 PM Meeting Wrap-Up: Outcomes and Future Directions (Organizers) Registered attendees can view abstracts starting on 02/23/2018
Place du Canada 7:00—8:00 PM Social Hour with Lite Bites No registration fees are used to fund alcohol served at this function.
Square Dorchester/Parc Mont Royal 8:00—11:00 PM Entertainment Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
Square Dorchester/Parc Mont Royal
WEDNESDAY, MARCH 28
Departure
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Directors' Fund
These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.
Click here to view all of the donors who support the Directors' Fund.
Keystone Symposia thanks our Sponsors for generously supporting this meeting: AstraZeneca BioLegend, Inc. Bristol-Myers Squibb Company Cancer Research UK Cell Research Incyte Corporation MedImmune Merck & Co., Inc. OncoMed Pharmaceuticals, Inc. Pfizer Inc. Regeneron Pharmaceuticals, Inc. Surface Oncology Takeda Pharmaceutical Company Limited TESARO, Inc. Thermo Fisher Scientific Inc.
We gratefully acknowledge additional support from these exhibitors at this conference:
Immudex USA, LLC
Please stop by to meet these exhibitors during the conference.
AI
